NCT00286156View on ClinicalTrials.gov

Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

March 31, 2012

Study Completion Date

December 31, 2014

Conditions
Polycystic Kidney Diseases
Interventions
DRUG

Rapamune

Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml Group 3- Standard Care

Trial Locations (1)

44195

The Cleveland Clinic- main campus, Cleveland

All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

The Cleveland Clinic

OTHER

NCT00286156 - Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Biotech Hunter | Biotech Hunter